Over 75% of all BC fall into the Luminal A or B HR + subtypes [60] and are usually selected to receive some form of endocrine therapy such as selective estrogen receptor modulators, selective estrogen receptor down regulators or aromatase inhibitors. Here, CYP19A1 is linked to breast cancer.